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Introduction: Advances in tendon engineering with mesenchymal stem cells (MSCs) are hindered by a need for
cues to direct tenogenesis, and markers to assess tenogenic state. We examined the effects of factors involved in
embryonic tendon development on adult MSCs, and compared MSC responses to that of embryonic tendon
progenitor cells (TPCs), a model system of tenogenically differentiating cells.
Methods: Murine MSCs and TPCs subjected to cyclic tensile loading, transforming growth factor-β2 (TGFβ2), and
fibroblast growth factor-4 (FGF4) in vitro were assessed for proliferation and mRNA levels of scleraxis, TGFβ2,
tenomodulin, collagen type I and elastin.
Results: Before treatment, scleraxis and elastin levels in MSCs were lower than in TPCs, while other tendon markers
expressed at similar levels in MSCs as TPCs. TGFβ2 alone and combined with loading were tenogenic based on
increased scleraxis levels in both MSCs and TPCs. Loading alone had minimal effect. FGF4 downregulated tendon
marker levels in MSCs but not in TPCs. Select tendon markers were not consistently
upregulated with scleraxis, demonstrating the importance of characterizing a profile of markers.
Conclusions: Similar responses as TPCs to specific treatments suggest MSCs have tenogenic potential. Potentially
shared mechanisms of cell function between MSCs and TPCs should be investigated in longer term studies.Introduction
Tendons transmit muscle-derived forces to bone to
enable skeletal movement. Unfortunately, these tissues
suffer ~15 million musculoskeletal injuries annually in
the USA [1]. Due to the poor innate healing ability of
tendons, surgical intervention is the primary approach
to repairing injured tendon despite substantial failure
rates, limited long-term function recovery, donor site
morbidity with autologous transplants, and risk of infec-
tions [2,3]. These significant drawbacks have motivated
efforts to engineer replacement tendon with mesenchy-
mal stem cells (MSCs) [4-9].* Correspondence: CatherineK.Kuo@tufts.edu
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unless otherwise stated.Adult MSCs are attractive for tissue regeneration strat-
egies as they have the potential to differentiate toward
various musculoskeletal lineages, including osteogenic,
chondrogenic and adipogenic, in response to established
lineage-specific cues. However, such cues have not been
identified for tenogenic differentiation, and tissue engin-
eering approaches to tenogenically differentiate MSCs
have not achieved functional tendons [4-14]. This may
be in part because evaluation of tenogenic differentiation
is challenged by limited knowledge of how tenogenically
differentiating cells should behave. Scleraxis (Scx) is the
only known tendon-specific marker that is expressed
during early development and sustained throughout
tissue formation [15]. However, Scx expression levels do
not vary in embryonic tendon progenitor cells (TPCs)
between developmental stages [16]. Furthermore, mice
with a mutation in the Scx gene have defects in only
a subset of tendons, indicating Scx is not a masterThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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limitations, we recently examined how a profile of tendon
markers, including Scx, late marker tenomodulin (Tnmd),and other relevant but non-specific markers (transforming
growth factor (TGF)β2, collagen type I (Col I) and elastin
(Eln)), respond to embryonic tendon cues [16].
We identified TGFβ2, and combinations with fibro-
blast growth factor-(FGF)4 and loading, as potential
in vitro tenogenic cues based on upregulation of Scx and
modulation of other tendon markers in embryonic
TPCs, a model system of tenogenically differentiating
cells [16]. Understanding how embryonic progenitor
cells respond to developmental factors has been success-
ful in establishing stem cell differentiation programs for
other lineages. For example, protocols to direct chondro-
genesis of adult MSCs are based on methods that utilize
embryonic cartilage development factors to chondro-
genically differentiate embryonic mesenchymal limb bud
cells [18,19]. Factors to guide stem cell differentiation
are selected based on their ability to induce marker
expression patterns similar to that exhibited temporally
by embryonic mesenchymal progenitor cells during de-
velopment [20-25]. In contrast, how MSCs respond to
treatments in comparison with embryonic cells that are
committed to the tendon lineage (that is, TPCs) has not
been investigated.
The need for mechanical loading for adult tendon
homeostasis has motivated application of dynamic tensile
loading as a primary cue to tenogenically differentiate
MSCs. However, reports on the effectiveness of loading on
tenogenesis have been inconsistent [6-8,10,26], and thus
the efficacy of dynamic tensile loading to tenogenically dif-
ferentiate MSCs is unclear. Developmentally, mechanical
loading seems critical for tendon formation [27,28], as
muscle paralysis during embryonic chick development re-
sulted in malformed tendons [29-31]. However, paralysis
may also have contributed to aberrant tendon formation
by altering soluble factors secreted by muscle, such as
FGF4 [32,33]. We reported mechanical loading alone had
little effect on embryonic TPC behavior, but that specific
loading and growth factor combinations differentially reg-
ulated tendon marker gene expression [16]. Interactions
between growth factors and dynamic loading could play a
key role in tenogenesis.
Tendon engineering strategies with MSCs have used
growth factors involved in adult tendon wound healing
[13,14], including TGFβ1, insulin-like growth factor,
platelet-derived growth factor, epidermal growth factor,
and FGF2 [34], despite their potential roles in the for-
mation of scarred tendon with aberrant biochemical
composition, organization and mechanical properties
[35]. In contrast, embryonic tendon development in-
volves different factors, including FGF4 and TGFβ2
[32,33,36-38]. Though we demonstrated FGF4 and TGFβ2
influence embryonic TPC activity [16], the ability for these
factors to tenogenically differentiate adult MSCs has not
been reported.
Brown et al. Stem Cell Research & Therapy  (2015) 6:89 Page 3 of 8We hypothesized that MSCs would mimic TPCs in
their response to tendon development factors. To test
this hypothesis, we treated mouse adult MSCs and em-
bryonic day (E) 14 TPCs with combinations of TGFβ2,
FGF4 and mechanical loading, and assessed proliferation
and gene expression. Our findings provide insight into
MSC tenogenic potential and the utility of embryonic
tendon factors to guide adult MSC differentiation toward
a tenogenic lineage in vitro.
Methods
All materials were from Invitrogen (Carlsbad, CA, USA)
unless otherwise specified.
Adult mouse bone marrow mesenchymal stem cell harvest
Four-month-old male Scx-green fluorescent protein
(GFP) mice [39] were sacrificed by CO2 asphyxiation and
decapitation with Tufts University Institutional Animal
Care and Use Committee approval. The hind limbs were
skinned, and femurs and tibias were dissected and washed
in sterile phosphate-buffered saline (PBS) without MgCl2/
CaCl2. Bone ends were removed and marrow was flushed
with PBS. Cell suspensions were treated with red blood
cell lysis buffer (Roche, Indianapolis, IN, USA), pelleted,
washed with PBS, and resuspended in growth medium
(GM) of Dulbecco’s modified Eagle medium with 10%
fetal bovine serum (FBS) and 1% penicillin/strep-
tomycin. Cells were plated at 1 × 106 cells/cm2 and
cultured at 37°C and 5% CO2. Three independent MSC
pools, isolated by plastic adherence [7], were expanded to
passage 3.
Embryonic mouse tendon progenitor cell harvest
E14 embryos were harvested from pregnant Scx-GFP
mice and staged [40] with Tufts University Institutional
Animal Care and Use Committee approval. Limbs were
isolated, minced, incubated under agitation at 200 rpm
in 1% type II collagenase in PBS at 37°C for 45 minutes,
and neutralized with GM. Cell suspensions were passed
through a 40-μm cell strainer (BD Biosciences, San Jose,
CA, USA), pelleted, washed in PBS, re-suspended in
GM, plated at 1 × 104 cells/cm2, and cultured at 37°C
and 5% CO2. Three independent limb cell pools were
harvested. Cells were trypsinized when 80% confluent
and sorted on the basis of GFP signal using a MoFlo
Legacy cell sorter (Beckman Coulter, Brea, CA, USA) at
488 nm excitation and collected by a 530/40 filter. TPCs
were expanded to passage 1–2.
Growth factor treatment and mechanical loading
TPCs and MSCs were seeded at 2 × 104 cells/cm2 on
Col I-coated Uniflex® plates (Flexcell International,
Hillsborough, NC, USA) and incubated in GM for cell
attachment. After 48 hours (day (D)0), GM was replacedwith basal (control) medium (BM; Dulbecco’s modified
Eagle medium, 1% FBS and 1% penicillin/streptomycin),
or BM supplemented with 100 ng/mL rhFGF4 and/or
1 ng/mL rhTGFβ2 (PeproTech, Rocky Hill, NJ, USA),
and cyclically loaded under uniaxial tension with 1%
sinusoidal strain at 0.5 Hz for 1 hour/day, as previ-
ously described [16]. Static controls were treated identi-
cally, without cyclic loading. Medium was replaced after
48 hours.
Cell proliferation
Cells were fixed for 20 minutes in 10% phosphate-
buffered formalin, stained with 4′,6-diamidino-2-pheny-
lindole nucleic acid dye, and imaged using an inverted Leica
DM IL fluorescent microscope and DFC340 FX camera
(Leica Microsystem, Buffalo Grove, IL, USA). Three fields
per well (left, middle, and right) were imaged for each
condition and cell pool. Nuclei were counted using Image
J (National Institutes of Health, Bethesda, MD, USA).
Quantitative polymerase chain reaction
MSCs and TPCs were harvested on D0 and D3 for
RNA isolation. Cells were homogenized in TRIzol re-
agent and total RNA was isolated. Samples were reverse-
transcribed using the Superscript III First Strand Synthesis
kit. Quantitative (q)PCR was performed with Brilliant II
SYBR Green qPCR master mix (Agilent, Wilmington, DE,
USA) on a Stratagene Mx3000P multiplex qPCR system
(Agilent). Previously optimized mouse-specific primers for
Scx, Tnmd, Col I, Eln, TGFβ2 and 18 s were used [16].
Fold change was calculated as 2–ΔΔCT.
Statistical analysis
Results were obtained from three independent cell pools
and are shown as mean ± standard deviation. Statistical
analyses were performed using GraphPad Prism (Graph-
Pad Software Inc., San Diego, CA, USA). Treatment
effects were evaluated using a two-way analysis of vari-
ance with Tukey's post-hoc test or Student’s t-test, and
considered statistically significant when P < 0.05. qPCR
data were log-transformed before statistical analysis and
plotted as fold difference values (2-ΔΔCT).
Results
Effects of treatments on mesenchymal stem cells
MSC number did not change with treatment or time
(P > 0.05; Figure 1A). MSCs appeared fibroblastic with
all treatments (not shown). On D3, Scx was downregu-
lated by FGF4 and FGF4 + loading, but upregulated
by TGFβ2 and TGFβ2 + loading (P < 0.05; Figure 2A).
FGF4 combinations downregulated TGFβ2 (P < 0.05;
Figure 2B). All combinations, except loading alone,
downregulated Tnmd (P < 0.05; Figure 2C). FGF4 and
FGF4 + loading downregulated Col I (P < 0.05). TGFβ2
Figure 1 Mesenchymal stem cell (MSC) and tendon progenitor cell (TPC) proliferation as a function of growth factor treatments and loading.
Effects on MSC and TPC proliferation on day (D)3 (normalized to D0) of treatment with combinations of mechanical loading (L), transforming
growth factor (TGF)β2 (T), and fibroblast growth factor-(FGF)4 (F) treatment. Left column shows D0 data. (A) MSC proliferation was not significantly
affected by any treatment. (B) TPC proliferation was not significantly affected by any treatment, but there was a significant difference between loading
and TGFβ2 + FGF4 + loading groups on D3. *P < 0.05.
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Figure 2D), with TGFβ2 + loading approaching signifi-
cance (P = 0.06). All treatments downregulated Eln at D3
compared to control (P < 0.05; Figure 2E).
Effects of treatments on tendon progenitor cells
TPC number did not change with treatment or time
(P > 0.05; Figure 1B), though was higher for TGFβ2 +
FGF4 + loading compared to loading alone on D3 (P < 0.05;
Figure 1B). TPCs appeared fibroblastic with all treatmentsFigure 2 Mesenchymal stem cell (MSC) tendon marker gene expression as
expression on day (D)3 of treatment with combinations of mechanical load
factor-(FGF)4 (F). Dashed horizontal line = 1 indicates control condition. (A)
loading, and upregulated by TGFβ2 and TGFβ2 + loading. (B) TGFβ2 was s
treatments except loading significantly downregulated tenomodulin (Tnmd).
FGF4 + loading, while all treatments involving TGFβ2 caused Col I to trend up (
↑ or ↓ indicates statistically significant up- or downregulation, respectively; *P<(not shown). On D3, Scx was upregulated by TGFβ2
combinations (P < 0.05), but was not affected by loading,
FGF4, or FGF4 + loading (Figure 3A). TGFβ2 and Tnmd
were downregulated by TGFβ2 + FGF4 + loading (P < 0.05;
Figure 3B,C), and exhibited similar expression patterns
with all treatments (Figure 3B,C). Col I was upregulated by
TGFβ2 + loading (P < 0.01), but not affected by other treat-
ments (Figure 3D). Eln was downregulated by FGF4 combi-
nations, but upregulated by TGFβ2 + loading (P < 0.05;
Figure 3E).a function of growth factor treatments and loading. MSC gene
ing (L), transforming growth factor (TGF)β2 (T), and fibroblast growth
Scleraxis (Scx) was significantly downregulated by FGF4 and FGF4 +
ignificantly downregulated by all treatments involving FGF4. (C) All
(D) Collagen type I (Col I) was significantly downregulated by FGF4 and
P≥ 0.06). (E) Elastin (Eln) was significantly downregulated by all treatments.
0.05, **P< 0.01, ***P< 0.001.
Figure 3 Tendon progenitor cell (TPC) tendon marker gene expression as a function of growth factor treatments and loading. TPC gene
expression on day (D)3 of treatment with combinations of mechanical loading (L), transforming growth factor (TGF)β2 (T), and fibroblast growth
factor-(FGF)4 (F). Dashed horizontal line = 1 indicates control condition. (A) Scleraxis (Scx) was significantly upregulated by all treatments involving
TGFβ2. (B) TGFβ2 and (C) tenomodulin (Tnmd) were significantly downregulated by TGFβ2 + FGF4 + loading. (D) Collagen type I (Col I) was
significantly upregulated by TGFβ2 + loading. (E) Elastin (Eln) was significantly downregulated by all treatments that involve FGF4, but was significantly
upregulated by TGFβ2 + loading. ↑ or ↓ indicates statistically significant up- or downregulation, respectively; *P< 0.05, **P< 0.01, ***P< 0.001.
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progenitor cell gene expression
Under control conditions and when loaded, Eln expression
in MSCs increased >20-fold from D0 to D3 (P < 0.001;
Figure 4A). Other treatment combinations had inhibitory
effects on this upregulation of Eln expression (Figure 4A).
In TPCs, Eln expression increased >15-fold from D0
to D3 in control culture and with loading (P < 0.05;
Figure 4B). This increase was abrogated by FGF4
combinations. In contrast to MSCs, TGFβ2 and TGFβ2 +
loading enhanced Eln expression in TPCs from D0 to D3
(P < 0.01; Figure 4B). Expression of other genes did not
vary with time (not shown).Figure 4 Elastin (Eln) gene expression as a function of growth factor treatm
(MSCs) and tendon progenitor cells (TPCs) on day (D)3 of treatment with c
(TGF)β2 (T), and fibroblast growth factor-4 (F), and normalized to D0. (A) M
loading. (B) TPCs significantly increased Eln with time in control culture and t
statistically significant up- or downregulation, respectively; *P < 0.05, **P < 0.01To investigate baseline differences between MSCs and
TPCs, tendon marker expression levels were compared
at D0. Scx and Eln expression in MSCs were lower (61-
fold and 138-fold, respectively) than in TPCs (P < 0.05;
Figure 5A). However, TGFβ2, Tnmd, and Col I levels
were similar between TPCs and MSCs (P = 0.82, P = 0.46
and P = 0.36, respectively; Figure 5A). To assess teno-
genic potential of MSCs, MSC response to TGFβ2 was
compared to that of TPCs at D3 (Figure 5B-F). TGFβ2
was chosen as a tenogenic factor for upregulating Scx in
TPCs. On D3 of TGFβ2 treatment, Scx, Col I, TGFβ2,
Tnmd and Eln expression trended up in both MSCs and
TPCs, compared to D0. MSCs and TPCs were notents and loading. Eln gene expression in mesenchymal stem cells
ombinations of mechanical loading (L), transforming growth factor
SCs significantly increased Eln with time in control culture and with
reatment with loading, TGFβ2, and TGFβ2 + loading. ↑ or ↓ indicates
, ***P < 0.001.
Figure 5 Comparison of mesenchymal stem cell (MSC) and tendon progenitor cell (TPC) tendon marker gene expression at baseline
and with transforming growth factor (TGF)β2 treatment. Comparison of MSC and TPC gene expression at day (D)0 and D3 of TGFβ2
treatment. (A) Comparison of tenogenic gene expression by MSCs versus TPCs at D0; scleraxis (Scx) and elastin (Eln) were significantly
lower in MSCs compared to TPCs. At D3 (normalized to D0) of TGFβ2 treatment, (B) Scx, (C) TGFβ2, (D) tenomodulin (Tnmd), and
(E) collagen type I (Col I) were not significantly different between MSCs and TPCs, while (F) Eln was significantly higher in TPCs than
MSCs. *P < 0.05.
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TGFβ2 (P = 0.13) and Tnmd (P = 0.17) levels (Figure 5B-E),
but the TGFβ2-induced increases in Eln were 21-fold
greater in TPCs than in MSCs (P < 0.05; Figure 5F).
Discussion
To date, a standard protocol to tenogenically differenti-
ate MSCs has not been established. A major challenge is
a need for potent tenogenic factors. Another significant
obstacle is a lack of metrics to assess tenogenic state.
We characterized the effects of embryonic tendon cues
on adult MSCs in comparison with embryonic TPCs.
Utilizing murine cells enabled investigation of embryonic
TPCs, which would not be possible with human cells.
Additionally, the murine system develops more rapidly
than human. Previous work demonstrated chondrogenic
growth factors induced murine embryonic limb bud cells
to form Sox9-expressing aggregates in 24 hours, and
sulfated proteoglycan-rich cartilaginous nodules by 3 days
[41]. Here, embryonic tendon development factors influ-
enced both MSCs and E14 TPCs within 3 days. At E14,
TPCs have just condensed into overt tendon tissue forms
in vivo [42], and embryonic muscle-induced movements
that could impose mechanical stimulation on developing
tendon are first observed [43]. Our results suggest MSCs
have tenogenic potential, based on similar responses as
E14 TPCs when subjected to tenogenic treatments.
MSCs and E14 TPCs were examined at D0 to compare
baseline gene expression profiles (Figure 5). At D0, cells
have been expanded in vitro but not subjected to treat-
ments, representing a starting point in many tissueengineering strategies. Tnmd and Col I are late markers
of tendon development, so it was expected that MSCs
and TPCs in early differentiation stages expressed both
genes similarly. Lower baseline Scx levels in MSCs com-
pared to E14 TPCs suggest MSCs are inherently less
committed to the tenogenic lineage than TPCs, while
similar TGFβ2 and Tnmd levels may reflect that E14
TPCs and MSCs are both at an immature stage of differ-
entiation. TGFβ2 may be a tendon marker as well as a
tenogenic cue. TGFβ2 is present in embryonic chick
tendons [36], expressed in murine E12.5 to E15.5 limb
tendons [37,44], and can upregulate Scx expression in
embryonic murine limbs in vivo [37]. Additionally,
TGFβ2−/− mice possess tendon defects [37].
Cyclic loading alone did not upregulate most tendon
markers examined, but increased Scx and Col I expres-
sion when combined with TGFβ2 (Figures 2 and 3). Our
study was performed with 1% FBS. In contrast, studies
in which dynamic loading enhanced Scx and Col I ex-
pression in MSCs used significantly higher serum levels
[6,8,10,26]. Loading likely interacted with soluble factors
from the serum to influence cell behavior in those stud-
ies. It is also possible that different loading parameters
could yield different results, though others found that
changing duty cycle did not affect MSC gene expression
of Col I and other extracellular matrix components [4].
Furthermore, we characterized gene expression, which
may not reflect changes at the protein level. We previ-
ously found cyclic loading enhanced collagen production
by human MSCs in three-dimensional scaffolds without
altering collagen mRNA levels [7]. Future studies that
Note: This article is part of an ‘Emerging Investigators’ collection
showcasing the work of early career investigators who have
demonstrated growing leadership in the field of stem cells and
regenerative medicine. Other articles in the series can be found
online at http://stemcellres.com/series/emerginginvestigators
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protein level changes will be important.
Both cell types did not change in cell number with treat-
ments (Figure 1) suggesting the treatments were possibly
influencing cell functions other than proliferation, such as
differentiation. TGFβ2 and TGFβ2 + loading induced
higher Scx expression in both MSCs and TPCs when com-
pared to control conditions on D3, though to different
levels (Figures 2A and 3A). Conditions that upregulated
Scx did not consistently upregulate other tendon genes, in-
cluding Col I and Tnmd, a reasonable finding as collagen
and Tnmd appear in significant amounts later in embryonic
development [45-47]. Over time, from D0 to D3, TGFβ2
treatment induced similar trends in Scx, Col I, TGFβ2, and
Tnmd expression by MSCs and TPCs (Figure 5B-E). Simi-
lar responsiveness of MSCs as TPCs to TGFβ2 treatments
compared to control conditions (Figures 2A and 3A) and
over time (Figure 5B-E) supports our hypothesis and sug-
gests MSCs have tenogenic potential.
In contrast to TGFβ2, FGF4 combinations downregu-
lated Scx in MSCs (Figure 2A) and had no effect on TPCs
(Figure 3A). FGF signaling seems necessary for embryonic
tendon development [33,38]. Thus, it was surprising that
FGF4 reduced tenogenic marker levels in MSCs. Perhaps
differences in composition of transcriptional regulators in
MSCs versus TPCs resulted in different signaling re-
sponses to the same cues. Potential effects of a heteroge-
neous progenitor cell population in MSCs should also be
considered. Elucidation of these differences could lead to
informed tenogenesis strategies using MSCs.
Differential baseline Eln expression levels and responses
to TGFβ2 and TGFβ2 + loading by TPCs compared to
MSCs are intriguing (Figures 4 and 5). Eln is important for
adult tendon function, but little is known about its involve-
ment in tendon development. In our earlier studies, Eln
fibers were not detected in embryonic limb tendon [46],
though tropoelastin was found in embryonic ligamentum
flavum [48]. It would be interesting to investigate Eln influ-
ences and elaboration in embryonic tendon development.
Conclusion
In summary, we showed MSCs have tenogenic potential,
based on similar gene expression and proliferation responses
as TPCs when subjected to tenogenic treatments. Distinctly
parallel trends in gene responses seen with MSCs compared
to TPCs suggest the cells share certain molecular mecha-
nisms of responses, which deserve further investigation. Fu-
ture studies over longer time points could identify TGFβ2
combinations that effectively tenogenically differentiate
stem cells, and may elucidate a chronological order of ten-
don marker expression during tenogenesis. Our findings
suggest continued investigation of MSC function in relation
to embryonic TPCs could contribute to advancements in
tendon tissue regeneration strategies.Abbreviations
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